Shares of fell 9 per cent in early trade on Tuesday, leading the top losers of Smallcap 100, as investors booked profits following a sharp rally in the stock driven by regulatory approvals for its novel antibiotic Zaynich in the US and India.
The stock traded at ₹1,966 on the at around 10.20 am, hitting a low of ₹1,958.40 against the previous close of ₹2,152.90.
The decline comes after the stock had surged 36.77 per cent over the last three trading sessions. Wockhardt shares had hit a 52-week high of ₹2,422.30 on the NSE on June 1, 2026, from the closing price of ₹1,771 recorded on May 27, 2026.
The recent rally in the stock followed the USFDA’s approval for Zaynich (cefepime and zidebactam), an intravenous antibiotic for treating adults with complicated urinary tract infections (cUTI).
Drug maker Wockhardt will market Zaynich on its own in international markets and India, Founder and Chairman Habil Khorakiwala said. The move marks a departure from the common pharmaceutical industry practice of partnering with other companies for global distribution.
the approval as a first for a new chemical entity developed from India.
Separately, the company informed stock exchanges on May 28, 2029, that the Central Drugs Standard Control Organisation (CDSCO) granted authorisation for the import and marketing of its indigenously discovered and developed breakthrough antibiotic Zaynich (Zidebactam/Cefepime) in India.